匹配药物和聚合物,以有效地输送抗炎药物:PLGA,聚胺和乙酸德克斯

相关实验视频

Updated: Jan 11, 2026

PLGA Nanoparticles Formed by Single- or Double-emulsion with Vitamin E-TPGS
12:48

PLGA Nanoparticles Formed by Single- or Double-emulsion with Vitamin E-TPGS

Published on: December 27, 2013

66.5K

Lea C Klepsch1,2, Philipp Dahlke3, Mira Behnke1,2

  • 1Laboratory of Organic and Macromolecular Chemistry (IOMC) Friedrich Schiller University Jena, Humboldtstraße 10, 07743 Jena, Germany. ulrich.schubert@uni-jena.de.

Journal of materials chemistry. B
|November 18, 2025
PubMed
概括

使用纳米颗粒药物递送系统解决了抗炎药物MF-15和BRP-201的低生物可用性. 封装干扰了MF-15的使用.

更多相关视频

Methionine Functionalized Biocompatible Block Copolymers for Targeted Plasmid DNA Delivery08:09

Methionine Functionalized Biocompatible Block Copolymers for Targeted Plasmid DNA Delivery

Published on: August 6, 2019

6.2K
Anionic Polymerization of an Amphiphilic Copolymer for Preparation of Block Copolymer Micelles Stabilized by π-π Stacking Interactions10:53

Anionic Polymerization of an Amphiphilic Copolymer for Preparation of Block Copolymer Micelles Stabilized by π-π Stacking Interactions

Published on: October 10, 2016

14.5K

相关概念视频

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention01:05

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

Body:Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
185
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
139